--2025/Q1-- / 79.538B--
--2024/Q4-- / 81.077B--
May 2, 20242024/Q165.349B / 63.573B--
US Stock MarketDetailed Quotes
NVO Novo-Nordisk A/S
- 85.730
- -1.640-1.88%
Close Dec 30 16:00 ET
- 85.560
- -0.170-0.20%
Post 20:01 ET
382.02BMarket Cap28.99P/E (TTM)
87.005High85.660Low6.11MVolume86.970Open87.370Pre Close526.64MTurnover0.19%Turnover Ratio33.01P/E (Static)4.46BShares147.59352wk High22.72P/B273.47BFloat Cap81.50052wk Low1.48Dividend TTM3.19BShs Float147.593Historical High1.73%Div YieldTTM1.54%Amplitude-3.073Historical Low86.194Avg Price1Lot Size
Novo-Nordisk A/S Key Stats
Novo-Nordisk A/S Q3 2024 Earnings Date
Highlights | Sales of the Q3 diet drug Wegovy surged, and operating profit increased 26%! Sales are expected to grow 23% to 27% for the full year of 2024
Currency：DKKNov 6, 2024
| Estimate (YoY) | Actual (YoY) | Vs Estimate (% Chg) | |
| Revenue | 71.87B | 71.31B | -558.36M |
| Miss Est. | +22.37% | +21.42% | -0.78% |
| EPS | 5.95 | 6.12 | +0.17 |
| Beat Est. | +19.03% | +22.40% | +2.83% |
Analyst Rating
Dec 20, 2024
Novo-Nordisk A/S Earnings Estimates
Revenue
EPS
EBIT
Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement
Currency: DKK
Actual
Estimate
Unlock Free Earnings Estimates
Open Account
Novo-Nordisk A/S Earnings Reports
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Price
% Chg
No Data
